I would say the cost to capture patients in the UK may be higher than Australia.
If Althea try to scale their business, they would be scaling their losses.
I guess this is what you get when you get a group of people with minimal pharma experience running a pharmaceutical business.
AGH's stock price is pretty much the lowest price it has ever been in the last 15 months for a reason. IMHO, I see the best solution is sacking the existing management and bringing in experienced pharma execs to replace the existing crew.
AGH Price at posting:
31.5¢ Sentiment: None Disclosure: Held
